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Factor V Leiden (Resistance to Activated Protein C) Increases the Risk of
Myocardial Infarction in Young Women
By F R. Rosendaal, D S. Siscovick, S.M Schwartz, R K Beverly, B M Psaty, W T Longstreth Jr, T E Raghunathan,
T D Koepsell, and P H. Reitsma
Factor V Leiden (factor V Arg506Gln), the genetic defect un-
derlying resistance to activated protein C, is the most com-
mon risk factor for venous thrombosis The relationship be-
tween this genetic abnormality and arterial disease is still
unresolved To assess whether factor V Leiden increases the
risk of myocardial infarction (MI), we conducted a popula-
tion-based case-control study among women 18 to 44 years
of age in western Washington state. We included 84 women
with first MI and 388 control women, ie, women residing in
the same area in the same age ränge without MI (n = 388)
The control women were contacted by random digit dialing
Data on risk factor Status were collected via personal inter-
view, and data on the factor V genotype via polymerase
chain reaction techniques The factor V Leiden mutation was
FACTOR V LEIDEN is the most common known heiedi-tary abnoimahty of the clottmg System, with a pieva-
lence of heterozygous carneis of 3% to 5% ' Due to a muta-
tion (Aig506Gln or R506Q) at the cleavage site foi activated
piotem C (APC), clottmg factor V is inactivated at a reduced
rate ' 4 This defect leads to a reduced anticoagulant effect of
APC (APC lesistance), with a less-than-expected prolonga-
tion of the activated partial thromboplastm time (APTT) ^
The reduced anticoagulant effect of the protein C/protem S
natural mhibitoi System leads to an mcieased tendency to
ward thrombosis 6 9
Several studies have demonstiated an association be-
tween resistance to activated piotem C and venous throm-
bos is 6 7 ' 0 1 4 Heterozygotes foi the abnoimality aie com
monly found among unselected patients with deep-vem
thiombosis (20%)6 and aie even moie frequent among
refeiied patients or patients with farmhal thiombophiha
(40-60%) 15 Compaied with those wilhout the mutation,
heterozygous cainers of the mutation have a sevenfold
mcieased nsk of venous thiombosis67, homozygous mdi-
viduals have a risk that is increased up to 100-fold 1S
Whethei factoi V Leiden influences the nsk of aitenal
disease is arguable, and few studies have investigated the
association Several reports, mcluding a controlled study
among patients with coionary Stenosis, aie suggestive of an
association with coionary heart disease,1720 but in seveial
othei contiolled studies no relationship was obseived 142121
The reason foi the lack of consistency among studies is
uncleai but may leflect diffeiences in the pievalence of othei
nsk factois that act syneigislically with factoi V Leiden
When the piesence of anothei factor is impoitant for mani-
festing the elevated risk, this interaction may go unobseived
m studies of selected groups of mdividuals among whom
this other factoi is absent 01 uncommon The conmcting
results also make it unhkely that factoi V Leiden is a majoi
nsk factoi foi aitenal thiombotic disease äs it is of venous
thrombosis Still, even if it had only a modeiate effect on
the nsk of myocaidial mfaiction (MI), 01 if it impaited a
large risk to d subgioup of the population, factoi V Leiden
would be important because of its high allele fiequency and
the large bürden of arterial disease in many populations
found more often in women with MI (10%) than among con-
trols (4%). The odds ratio for MI was 2 4 [95% confidence
interval (Cl) 1 0 to 5.9]. The risk was increased fourfold (Clgs
1.2 to 12.1) when adjusted for major cardiovascular risk fac-
tors. Among nonsmokers the factor V Leiden mutation had
little effect (odds ratio 1.1, CI95 0.1 to 8.5), whereas it had
a large effect among smokers (odds ratio 3 6, 0195 0 9 to
14 4), which, because smoking was itself a strong risk factor
for MI, led to an odds ratio for smoking carriers of the muta-
tion that was 32-fold increased compared with nonsmoking
noncarriers. We conclude that factor V Leiden increases the
risk of MI in young women. This effect seems to be confined
largely to current smokers
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We studied the effect of factor V Leiden on the occurrence
of MI among young women in an ongoing population-based
case-contiol study of myocaidial mfaiction and stroke Be-
cause thrombotic factois aie hkely to be most impoitant in
a gioup of young mdividuals among whom atherosclerosis
is less pievalent than it is among older subjects, this study
piovided an excellent opportunity to assess the association
of factoi V Leiden with arterial vascular disease Moieover,
in this population-based study of young patients, other risk
factors, such äs smoking, are highly prevalent, enhancmg
the potential to detect potentially important mteiactions
among risk factors 24
METHODS
General design We conducted a population-based case control
study of MI among women 18 to 44 years of age residing in thiee
contiguous counties of westein Washington state The goal was to
mclude all quahfymg patients with a fiist myocaidial infarction dur-
ing the time fiame of the study Data collection was achieved via
peisonal interview, leview of medical recoids and analysis of blood
samples This study also mcludes young women with stioke (n =
105, 40 ischemic strokes), among whom we found no excess number
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of caniers öl factor V Leiden and about whom we will not leport
furthei heie
Recrmtment of patients Eligible patients weie all 18 to 44-
year-old female lesidents of King, Pieice, or Snohomish Counties,
Washington, with no pnor histoiy of coionary heart disease or ceie-
brovascular disease, who weie diagnosed between July l, 1991, and
Februaiy 28, 1995, wilh a first acute MI Cases weie identified
thiough the leview of Hospital discharge diagnoses and incident
repoits fiom cmergency medical-service Systems Cntena for MI
weie adapted from the Caidiovasculai Health Study21 and were de-
fmed by evidence of Symptoms, elevated enzymes, and electrocar-
diographic changes Usmg these procedmes, we identified 165 eligi-
ble patients with MI, of whom 112 could be contacted and were
wilhng to participate m an in peison interview
Reciuitment of controls We used landom digit lelephone dialmg
to identify a sample of women 18 to 44 years of age hvmg in the
same aiea dunng the time penod of the study 26 A household census
was completed foi 949% of the lesidences contacted Among the
age-ehgible (ιέ, matched to the age distnbution of the cases) women
identified, we landomly chose 691 (one from each household) to be
lecruitcd into the study Seven of these women were excluded due
to a pnoi histoiy of caidiovasculai disease 01 an mability to speak
Enghsh We completed an m-person inleiview with 525 of the re-
maimng 684 women for an oveiall response of 72 8% (525/684 X
0949)
Data collection Paiticipating cases and tontrols weie inter-
viewed in person legarding histones of diabetes hypertension, and
hyperhpidemia, cigarette smoking, height and weight, reproductive
and contraceptive histones, and demographic charactenstics All
questions elicited miormation fiom a time penod befoie each wom-
an's caidiovasculai event, or an equivalent date foi controls
In addition, we obtamed a 30 mL nonfasting venous blood sample
from 84 patients (75%) and 391 (74%) controls who weie mter
viewed We compared the women who were inteiviewed and gave
blood with those interviewed who dechned venipunctuie and found
no impoitant diffeiences Blood was diawn from the antecubital
vein in EDTA-treated vacutamers and separated by centnfugation at
2,000g for 10 mmutes, the buffy coat was resuspended m phosphate-
buffeied sahne and frozen at -70°C White cell ahquots weie
shipped to Leiden, The Netheilands, where DNA analysis was per-
foimcd DNA was extracted from these samples äs descnbed by
Millar et al2 7 The presence of the factor V mutation (1,691, G -> A
leplacement) was infened fiom the loss of an Mnl I lestnction site
äs ongmally descnbed by Bertina et al ' The technicians weie
blinded to whether a specimen was fiom a case subject or contiol
subject Analyzable DNA was available for 84 women with MI and
388 contiol subjects
Analysis We classificd äs smokers any woman who lepoited
smoking cuirently and regulaily, and all otheis äs nonsmokers
Women who reported still having menslrual peiiods were classihed
äs premenopausal, mcluding women who weie currently piegnant
or nursing A woman was classified äs diabetic, hypertensive, 01
hypeicholcsterolemic if she reported that she was currently takmg
piescnption drugs foi these conditions, and äs obese when hei body
mass mdex (BMI) was equal to 01 exceeded 27 3 kg/m2 These lattei
four vanables were giouped together äs metabohc nsk factois
The association of camership of the factor V Leiden mutation
with MI was exammed by simple cioss-labulation and by the calcula-
tion of the odds ratio äs a measure foi lelative nsk Adjustment loi
age was performed usmg unconditional logistic legression, m most
instances, unadjusted estimates aie given betause adjustment did not
change the estimates The extent to which the associalion belween
factoi V Leiden and disease was modified by olhci chaiactenstics
was assessed thiough stiatified analyses Conhdence mtervals (CI95)
Table 1 General Charactenstics of Patients and Controls
Age (yr)
Mean
Range
Premenopausal
Current smokers
Currently treated for
Hypertension
Hypercholesterolemia
Diabetes mellitus
Obese
Patients With MI
(n - 84)
396
23 44
57 (68)
62 (74)
14 (17)
2 (2)
6 ( 7 )
51 (62)
Controls
(n - 388)
377
19 44
343 (88)
87 (22)
10 (3)
2 (1)
3 (1)
104 (27)
Missing are data on BMI in three controls and on hypercholesterol
emia m one control Percentages are in parentheses
weie calculated usmg standatd mcthods, le, by Woolf's method 01
from the logistic legiession model
RESULTS
The majonty of the women weie 35 to 44 yeats of age,
with a mean age of 38 years (Table 1) Of the 472 women,
72 (15%) had leached menopause (all but foui via hysterec-
tomy or bilateial oophorectomy), 47 (10%) used oral contra-
ceptives Most of the women weie white (89%) Table l
furthei shows the distnbution of several major nsk lactors,
le, current smoking, pharmacologically tieated hypercholes-
terolemia, hypertension, and diabetes mellitus, and obesity
(BMI s; 27 3 kg/m2) As expected, these factors weie more
common m the patients than m the contiols
Ten percent of the women who had sustamed MI carned
the factor V Leiden mutation (8 of 84, 9 5%), compared with
4 1% (16 of 388) of the conlrols (Table 2) The odds latio
associated with factor V Leiden foi MI was 2 4 (CI95 l 0
to 5 9) Adjustment for age yielded a similar result (odds
ratio 2 4, CI95 l 0 to 5 8) This association changed only m
trivial ways when the analysis was lestncted to the white
women (OR 2 1), the premenopausal women (OR 2 5), 01
the women not usmg oral conti aceptives (OR 2 5) The odds
ratio adjusted for age and major cardiovasculai nsk factors
(smoking, diabetes, hypercholesteiolemia, hypeitension and
obesity) was 4 0 (CI95 l 2 to 12 1)
Current smoking and the presence of metabohc nsk fac-
tors weie strong nsk factors foi MI Of the patients with MI,
62 (74%) were smokers, compared with 87 (22%) of the
controls, smoking was associated with a neaüy tenfold m-
creased nsk (OR 9 8, CI95 5 7 to 16 8, age-adjusted OR 8 6,
CI95 5 4 to 13 7) One or more of the metabohc nsk factois
(hypertension, diabetes mellitus, hypeicholesteiolemia, and
obesity) were piesent in 59 (70%) of the patients with MI
and 110 (29%) of the control subjects, which mdicates a
sixfold mcreased nsk for women with one or moie of these
nsk factois äs compaied with women with none of these
factois (OR 5 9, CI95 3 5 to 9 9)
Further analyses explored whether the nsk associated with
factor V Leiden was diffeient for women with othei majoi
risk factois compaied with women without othei major nsk
factors Odds latios were calculated foi each combination of
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Table 2 Factor V Leiden Among Patients With MI and Controls
Patients With
MI (n = 84)
Controls
(n - 388)
Table 4 Factor V Leiden and Metabolie Risk Factors
Separate and Combmed Effects on MI
Factor V Leiden (AG)
Factor V wild type (GG)
8 ( 9 5 )
76 (90 5)
16 (4 1)
372 (959)
Valuesarethe number of patients with percentages m parentheses
nsk factors (Tables 3 and 4) The simultaneous presence of
factoi V Leiden and eithei smokmg or one or more ot the
metabolic nsk factoi s led to a 25- to 32-fold mcreased nsk
compared with those without factor V Leiden and smoking
(Table 3) or without factoi V Leiden and one 01 moie meta-
bolic nsk factors (Table 4) When we compared the nsk of
individuals who eithei smoked 01 had one of the metabolic
nsk factors and canied the factoi V Leiden mutant gene
(eight cases, five controls), lelative to those who did not
smoke, had none of the metabolic nsk factoi s, and did not
carry the factoi V Leiden gene (3 cases, 202 contiols), the
odds latio mcieased markedly to 108 (CI95 22 to 532)
The lesults shown in Tables 3 and 4 indicate that factoi
V Leiden cameiship leads to the highest nsk when othei
nsk factois aie also present, although the small number of
mutant gene carners do not allow foimal stalistical tests foi
mteiaction to reach sigmficance The presence of one or
moie of the metabolic nsk factois and factoi V Leiden (Table
4) each mcrease the nsk, which is highest when both aie
piesent, factoi V Leiden cameiship incieases the nsk among
those with one 01 moie metabolic nsk factors (OR 3 9, CI95
0 7 to 22 1) äs well äs among those without one of these
fom metabolic nsk factois (OR 3 6, CI95 l ] to 11 7) For
smoking the lesults aie diffeient the combmed effect of
smoking and factoi V Leiden, which has a high odds latio
of 32, much exceeds the separate effects of these two factois
because smokmg appeais to be a pieiequisite for the iisk-
mcieasing effect of factoi V Leiden, cameiship of factoi V
Leiden increases the nsk among smokeis (OR 3 6, CI95 0 9
to 144) but not among nonsmokeis (OR l l, CI95 0 l to
8 5) In the most extensive model, with adjustment for age
and the piesence of one 01 more melabohc nsk factois, the
nsk was mcreased moie than 50-fold in women who smoked
and camed the mutation äs compaied with nonsmoking non-
carneis (OR 52 5, CI95 11 2 to 247)
DISCUSSION
MI is a i aie event in young women Seveial well-known
nsk factors (hypercholesteiolemia, hypeitension) are also
Table 3 Factor V Leiden and Current Smoking
Separate and Combmed Effects on MI
Current
Smoker
No
No
Yes
Yes
Factor V
Genotype
Wild type
Leiden
Wild type
Leiden
Patients
21
1
55
7
Controls
288
13
84
3
OR*
1
1 1
90
320
CI95
0 1 8 5
5 1 157
77 133
Risk Factors*
None
None
One or more
One or more
Factor V
Genotype
Wild type
Leiden
Wild type
Leiden
Patients
21
4
55
4
Controls
260
14
108
2
ORt
1
35
63
248
CI95
1 1 1 1 7
36 109
4 5 194
* All odds ratlos are relative to the reference category, le those
who did not smoke and did not carry the mutation Age adjusted
logistic regression led to similar odds ratios
* Obesity (BMI =- 27 3) treated hypertension, diabetes, or hypercho
lesterolemia, or combmations of same (these data were missmg in
four controls)
t All odds are relative to the reference category le those who did
not have any of these four nsk factors and did not carry the mutation
Age adjusted logistic regression yielded similar odds ratlos
uncommon m the young, which makes this particulai group
well suited to mvestigate new causes of MI This is espe-
cially the case foi thrombotic nsk factois, which may have
a stilking effect m a population in which atheiosclerosis has
had less time to progiess Theiefoie, young women aie an
excellent gioup to mvestigate whethei factoi V Leiden m-
cieases the nsk of MI
Factor V Leiden has been shown to be a stiong and com-
mon nsk factor foi venous thrombosis " l628 From the pres-
ent study it appears that it is also a deteimmant of myocardial
infaiction m young women, mcieasmg the nsk about four-
fold when othei major risk factois foi MI are taken mto
account
Although we could not mclude women who did not sui-
vive the MI 01 women who refused the interview or the
venipunctuie, it is unhkely that this led to biased results It
is mconceivable that nonresponse would be determmed by
factor V genotype, whereas it is also not hkely that the
women who had died (a much smallei numbei) would have
had an ovei- 01 undei-representation of the mutant gene
The ovei all mciease in the risk foi MI was confined to
women who weie current smokers, and the mteiaction with
smoking appeaied stiong Smoking women who cariied the
factoi V Leiden mutation had a 32-fold mcreased nsk of
MI (50-fold in the most extensive model), wheieas the risk
appeaied not to be mcreased at all m nonsmoking gene carri-
ers These associations are strong but must be mteipieted
with some caution First, the mcidence of MI m young
women is low, theiefore, even a small mcrease m the numbei
of events on an absolute scale leads to laige relative iisks
The findmgs thus aie unhkely to be directly apphcable to
populations with a higher oveiall baselme nsk, such äs oldei
women and men Second, oui estimates aie based on small
numbeis that aie subject to consideiable statistical uncer-
tainty Nevertheless, one may speculate why factoi V Leiden
has a synergistic effect with cigarette smokmg in young
women Both aie eithei fully 01 paitially piothrombotic fac-
tors, wheieas the metabolic factors we mvestigated aie
mamly atheiogenic Since by its chronicity atheioscleiosis
takes more time, it is conceivable that the combmed effect
ot prothrombotic factois Stands out most shaiply m young
individuals
Seveial studies have addiessed the effect of factoi V
2820 ROSENDAAL ET ΑΙ-
Leiden on coronary artery disease Holm et al reported two
women who had MI at the uncommonly young age of 33
and 34 years and who both were homozygous for the factor
V mutation 18 In another case senes29 of 60 patients, and
several controlled studies,1421 23 no excess of caniers of fac-
tor V Leiden were found among patients with MI In another
large study, however, among 224 patients with angiographi-
cally demonstrated coronary artery disease, the factor V mu-
tation was found more often m the patients than in 196
controls, with an odds ratio of 2 4 19 In a recent study from
Fmland, the factor V Leiden gene also was found more often
m patients with MI (5 7%) than m controls (2 9%) 20
The discrepancies among studies may well be the result
of differences in study populations Most of the previous
studies mcluded exclusively or predommantly men The eti-
ology of MI may m part diffei between men and women
At the biochemical level, it has been demonstrated that estro-
gens, endogenous äs well äs exogenous, mciease the resis-
tance to APC in women who carry the mutation äs well äs
in women who do not In other words, it seems that estrogens
further lower the mactivation rate of factor Va by APC 10 It
is therefore possible that factor V Leiden is mamly a nsk
factor in women The effect of oral contraceptives m increas-
ing the nsk of MI is enhanced by smokmg 24 Previously we
descnbed an interaction between factor V Leiden and the
use of oral contraceptives on the nsk of developmg deep-
vein thrombosis Ή The small number of oral conti aceptive
users did not allow us to mvestigate this issue here for MI,
and additional studies will be needed to clanfy the role and
possible interplay of factor V Leiden, smokmg, and esüo-
gens in MI
If the effect of factor V Leiden on MI is mamly brought
about by an interaction with current smokmg, this findmg
also may explam the conflicting results reported so far The
Physicians' Health Study14 was conducted äs a nested case-
control analysis among male U S physicians who consented
to participate in a randomized tnal of pnmary prevention
and who were followed piospectively The number of current
smokers among subjects who developed MI was only 16%,
which is far lower even than the prevalence m the general
population of men m the United States This extremely low
prevalence of smokmg may explam why no association be-
tween factoi V Leiden and MI was observed m that highly
selected cohort, whereas we did find a lelationship m our
population-based study of young women among whom
smokmg was prevalent (74% of the women with MI)
In conclusion, factor V Leiden is a nsk factor for MI m
young women Because of its high prevalence compared with
other genetic mutations relevant to thrombosis, the effect of
factor V Leiden m populations of other age and sex, m
association with other nsk factors, needs to be further deter-
mmed
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